Clinical Efficacy and Patient-Reported Outcomes from Phase 3 IMerge Trial

Clinical Efficacy and Patient-Reported Outcomes from Phase 3 IMerge Trial

Panelists discuss how the IMerge trial data demonstrate imetelstat’s efficacy in SF3B1-negative patients with lower-risk MDS who failed ESA therapy, achieving substantial hemoglobin improvements (averaging 4-5 g/dL in responders) with meaningful transfusion independence rates. They debate the clinical significance of modest patient-reported quality-of-life improvements and question whether historical hemoglobin ceiling limits should be reconside…